DNA vs PHAT

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 12, 2026

DNA

50.2
AI Score
VS
PHAT Wins

PHAT

65.3
AI Score

Investment Advisor Scores

DNA

50score
Recommendation
HOLD

PHAT

65score
Recommendation
STRONG BUY

AI Analyst Insights

Detailed Metrics Comparison

Metric DNA PHAT Winner
Forward P/E 0 5.7937 Tie
PEG Ratio 0 0 Tie
Revenue Growth -5.7% 71.1% PHAT
Earnings Growth 0.0% 0.0% Tie
Tradestie Score 50.2/100 65.3/100 PHAT
Profit Margin -192.0% -30.2% PHAT
Beta 1.00 1.00 Tie
AI Recommendation HOLD STRONG BUY PHAT

Relative Price Performance (Last 90 Days)

DNA 1M: -11.8% · 3M: +49.8% PHAT 1M: -15.3% · 3M: -34.6%

Current Technical Phase

DNA

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 47

RSI (14): 46.8 · Price: $10.17

PHAT

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 50

RSI (14): 49.7 · Price: $6.27

Fundamentals Snapshot

Metric DNA PHAT
Market Cap — —
Forward P/E -3.5 6.6
Trailing P/E — —
Revenue (TTM) — —
Revenue Growth -0.1% 0.7%
Gross Margin 0.7% 0.8%
Operating Margin -1.6% 0.0%
EPS -4.24 -1.01
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, PHAT is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.